Article
Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
BMC cancer - 31 Oct 2019
Carroll Molly J, Parent Carl R, Page David, Kreeger Pamela K
Abstract excerpt
BACKGROUND: Genetics-based basket trials have emerged to test targeted therapeutics across multiple cancer types. However, while vemurafenib is FDA-approved for BRAF-V600E melanomas, the non-melanoma basket trial was unsuccessful, suggesting mutation status is insufficient to predict response. We hypothesized that proteomic data would complement mutation status to identify vemurafenib-sensitive tumors and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.